Adial Pharmaceuticals Collaborates with Genomind to Develop Precision Medicine Testing Solution
Adial Pharmaceuticals' Milestone: Adial Pharmaceuticals has successfully completed the analytical validation of a cheek swab collection method for testing patients, a significant step towards FDA registration for their treatment AD04, aimed at Alcohol Use Disorder (AUD).
Collaboration with Genomind: The partnership with Genomind has enabled Adial to develop a validated gene test to identify key SNPs in the serotonergic system, facilitating patient selection for the upcoming Phase 3 clinical program for AD04.
Get Free Real-Time Notifications for Any Stock
Analyst Views on ADIL
About ADIL
About the author
Adial Pharmaceuticals Enters Warrant Inducement Agreement, Raising $2.86 Million
- Financing Agreement Reached: Adial Pharmaceuticals has entered into a warrant inducement agreement with an existing institutional investor, enabling the immediate exercise of existing Series C-1 Warrants to raise approximately $2.86 million, enhancing the company's liquidity to support R&D and operations.
- Warrant Details: The investor will receive new unregistered Series F Warrants to purchase up to 13,823,512 shares of Common Stock at an exercise price of $0.31, which will expire 24 months after shareholder approval, further enhancing the company's capital structure flexibility.
- Market Reaction Anticipated: This financing is expected to provide Adial with essential funding to advance its research in addiction treatment, particularly for its investigational drug AD04 targeting Alcohol Use Disorder, potentially boosting future market performance.
- Transaction Timeline: The closing of this transaction is expected around December 1, 2025, subject to customary closing conditions, demonstrating the company's proactive and strategic approach in capital market operations.
Adial Pharmaceuticals Announces Financial Results for Q3 2025 and Offers Business Update
Business Update: Adial Pharmaceuticals reported progress towards FDA approval for its lead drug AD04, aimed at treating Alcohol Use Disorder (AUD), following a successful End of Phase 2 meeting with the FDA that provided guidance for the upcoming Phase 3 study.
Legislative Support: Recent bipartisan support from the U.S. Senate encourages the expansion of clinical trial endpoints beyond abstinence, aligning with Adial's focus on reducing alcohol consumption and cravings, which reinforces their patient-centered treatment approach.
Partnership and Testing: Adial has partnered with Genomind to develop a precision medicine testing solution, completing validation for a genetic test that identifies eligible patients, which is crucial for clinical trials and future commercial use.
Financial Overview: As of September 30, 2025, Adial reported $4.6 million in cash, with a net loss of $1.8 million for the quarter, reflecting a decrease in research and development expenses compared to the previous year.
